Download Image
    
Share
  
Post
Cenicriviroc for COVID-19
3 studies with >1,000 patients
Hospital Icon Control
Hospital Icon Cenicriviroc Serious Outcome Risk
COVID-19 Cenicriviroc studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -28% Mortality -28% Hospitalization -17% Recovery -2% RCTs -28% RCT mortality -28% Late -28% Favorscenicriviroc Favorscontrol
Jul 25
2023
 O’Halloran et al., JAMA, doi:10.1001/jama.2023.11043 Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia
30% higher mortality (p=0.15), 8% worse improvement (p=0.62), and 1% improved recovery (p=0.91). RCT 723 hospitalized COVID-19 patients showing no significant difference in outcomes with cenicriviroc treatment.
Mar 31
2023
 Kurth et al., Journal of Global Antimicrobial Resistance, doi:10.1016/j.jgar.2022.12.004 Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial
500% higher need for oxygen therapy (p=0.26), 100% worse recovery (p=0.55), and 17% longer hospitalization (p=0.42). RCT 30 hospitalized COVID-19 patients showing no significant difference in clinical improvement with cenicriviroc (CVC) treatment compared to placebo.
Mar 3
2023
 Files et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.101889 Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial
24% higher mortality (p=0.28) and 14% worse recovery (p=0.46). RCT 261 severe COVID-19 patients showing no significant difference in outcomes with cenicriviroc.